Nicholas Robert, MD – Chief Medical Officer of Ontada Nicholas J. Robert, the chief medical officer at Ontada, is responsible for enhancing the clinical focus and expertise of the organization, ensuring the highest scientific standards and clinical relevance in studies, real-world data offerings, and educational programs, building on his extensive experience as a practicing oncologist and his previous role as VP, Medical Affairs at Ontada overseeing the development of real-world evidence studies and consortium protocols. Triple negative breast cancer (TNBC) is known to have a higher incidence in African American women compared to European American women and is associated with…
Author: Editor
Majid Jaberi-Douraki, PhD -Kansas State University and Shahzad Raza, MD – Cleveland Clinic This study analyzed data from the FDA Adverse Event Reporting System (FAERS) to evaluate global disparities in multiple myeloma (MM) and drug toxicity trends. The analysis of adverse events (AEs) associated with FDA-approved MM drugs revealed variations in AE incidence based on age, sex, and geographical regions. Disparities were observed in specific AEs such as cardiotoxicities, vascular toxicities, nephrotoxicity, peripheral neuropathies, secondary neoplasms, and respiratory tract neoplasms, which may be influenced by factors like genetics, dosing/regimen, comorbidities, age, and sex. These findings highlight the importance of further…
Scott T Tagawa, MD, MS, FASCO, FACP – Weill Cornell This study explores the use of a combination therapy, involving both alpha and beta radioligands, for prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) in patients with metastatic castration-resistant prostate cancer. The preliminary phase I results indicate the feasibility and safety of combining the alpha-radiolabeled antibody 225Ac-J591 with the beta-radioligand 177Lu-PSMA I&T. Promising efficacy outcomes, such as PSA decline and favorable circulating tumor cell changes, are observed, and further evaluation will be conducted in the phase II portion of the study.
Qing Zhou, MD – Guangdong Lung Cancer Institute Preliminary data from a phase I/II study of KL590586, a next-generation selective RET inhibitor, show promising results in patients with RET-altered solid tumors. The drug demonstrated good tolerability and substantial clinical activity, including in non-small cell lung cancer (NSCLC) patients with resistance to first-generation inhibitors and those with brain metastases. These findings support the advancement of KL590586 to pivotal studies for further evaluation.
Ari Rosenberg, MD – University of Chicago The DEPEND trial investigated the use of neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). The study aimed to determine the feasibility of this treatment approach and assess its impact on long-term toxicities. The results showed that neoadjuvant chemoimmunotherapy with nivolumab led to deep responses, and response-adapted chemoradiation was associated with favorable survival and locoregional control. Additionally, the expression of PD-L1 was found to be predictive of a deep response to neoadjuvant therapy.
by: Niels Van de Donk, MD, Amsterdam UMC Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show promising results in patients with relapsed/refractory multiple myeloma (RRMM) based on long-term follow-up from the MajesTEC-1 study. After approximately 2 years of follow-up, patients treated with teclistamab achieved deep and durable responses, with a median progression-free survival of 12.5 months and a median duration of response of 24 months. These findings support teclistamab as a safe and effective off-the-shelf BCMA bispecific therapy for RRMM patients.
Glenn Hanna, MD – Dana-Farber The combination of BCA101 and pembrolizumab as first-line therapy in patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) shows promising anti-tumor activity, especially in HPV-negative patients, with manageable side effects. These dose expansion results highlight the potential of this combination treatment and support the need for further investigation. The study, funded by Bicara Therapeutics and conducted in collaboration with Merck Sharp & Dohme LLC, demonstrates the clinical potential of BCA101 and pembrolizumab in this patient population (Clinical trial information: NCT04429542).
Omid Hamid, MD – The Angeles Clinic This phase 1/2 study evaluated the combination therapy of retifanlimab, INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) in patients with advanced solid tumors. The study aimed to determine the optimal doses, safety, and efficacy of these monoclonal antibody combinations. Initial results showed that the doublet and triplet regimens were well tolerated, with no significant new side effects observed. Further evaluation of the optimal doses is ongoing, with a focus on first-line treatment for melanoma. Clinical trial information can be found under NCT04370704.
Laure-Anne Teuwen, MD, PhD from Antwerp University Hospital, and Joanna Young, DO, FACP from Blue Ridge Cancer Care examined the endpoints evaluated in phase 3 randomized clinical trials (RCTs). The objective of phase 3 RCTs is to demonstrate clinically meaningful benefits for patients. The researchers conducted a systematic analysis of ASCO22 abstracts from phase 3 RCTs, focusing on primary, secondary, interim, updated, and subgroup analyses. They excluded posthoc, exploratory, biomarker, and retrospective analyses of RCTs. The analysis identified a total of 166 RCTs, with 93 trials involving 50,781 enrolled patients and 73 trials expected to enroll 52,098 patients. The majority…
Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials. Urothelial carcinoma is the most common type of bladder cancer, and advanced cases are challenging to treat. The KEYNOTE-045 trial was a landmark study evaluating the efficacy and safety of pembrolizumab compared to chemotherapy as a second-line treatment for advanced UC. The results of this trial demonstrated that pembrolizumab significantly improved overall survival and had a favorable safety…
Prof. Arun Azad, MBBS, PhD from the Peter MacCallum Cancer Centre, has recently conducted a Phase 3 clinical trial called TALAPRO-2. The study aimed to evaluate the efficacy of a combination therapy consisting of talazoparib (TALA) and enzalutamide (ENZA) as a first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) gene alterations. Metastatic castration-resistant prostate cancer is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormonal therapies. Homologous recombination repair gene alterations are genetic mutations that impair the ability of cancer…
Monique Hartley-Brown, MD, MMSc, from Dana-Farber Cancer Institute, conducted a significant clinical study called “SUCCESSOR-2” that focused on the treatment of relapsed/refractory multiple myeloma (RRMM). This Phase 3 study aimed to compare the efficacy and safety of a combination therapy called MeziKd (mezigdomide, carfilzomib, and dexamethasone) versus the standard therapy of carfilzomib and dexamethasone (Kd). Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. While there have been significant advancements in treatment, RRMM remains a challenging condition to manage. Therefore, exploring new therapeutic options is crucial to improving patient outcomes. The SUCCESSOR-2 study utilized…
Karan Dixit, MD, from Northwestern Medicine, delivered a compelling presentation during the Plenary Session at the recent conference on glioma research. His talk centered around the highly anticipated LBA1 INDIGO phase 3 trial, which holds significant promise for the treatment of glioma, a type of brain tumor. Glioma is a challenging and aggressive form of brain cancer that poses substantial difficulties in treatment and management. Existing treatment options often fall short in providing long-term benefits, highlighting the critical need for novel therapeutic strategies. The INDIGO phase 3 trial aims to address this issue by investigating the efficacy and safety of…
Rona Yaeger, MD, an eminent oncologist from Memorial Sloan Kettering Cancer Center, is currently involved in a significant clinical trial called A022004, conducted by the Alliance for Clinical Trials in Oncology. This trial aims to evaluate the effectiveness of consolidation-targeted adjuvant therapy using encorafenib and cetuximab compared to usual care for patients diagnosed with stage II/III BRAF V600E colon cancer. Stage II/III colon cancer refers to cancer that has spread beyond the inner lining of the colon into the surrounding tissues or nearby lymph nodes. BRAF V600E is a specific mutation found in the BRAF gene, which is associated with…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR, investigating the efficacy of Tumor Treating Field (TTFields) therapy combined with standard of care (SOC) in patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced platinum failure. The study aimed to evaluate whether the addition of TTFields therapy to SOC could improve overall survival (OS) and progression-free survival (PFS) compared to SOC alone in this patient population. TTFields therapy is a novel treatment modality that involves the use of electric fields to disrupt cancer cell division, thereby inhibiting…
Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions to the understanding of fibroblast growth factor receptor 3 (FGFR3) alterations in the context of PROOF 302, a phase III clinical trial evaluating the efficacy of infigratinib (BGJ398) as adjuvant therapy for invasive UC patients. Invasive UC is a type of bladder cancer that has spread beyond the inner layer of the bladder. The treatment landscape for UC has evolved rapidly in recent years, with the discovery of FGFR3 alterations offering new therapeutic opportunities. FGFR3 is a receptor protein that…
Sara Tolaney, MD, a renowned researcher from the Dana-Farber Cancer Institute, has recently conducted a groundbreaking study that has been recognized by our editorial team for its significant contribution to the field of breast cancer treatment. The study focuses on the final overall survival (OS) analysis from the phase 3 TROPiCS-02 trial, which evaluated the efficacy of sacituzumab govitecan (SG) in patients with hormone receptor-positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). Metastatic breast cancer, characterized by the spread of cancer cells to other parts of the body, remains a challenging condition to treat effectively. In recent years, targeted therapies have shown…
Jason Luke, MD, FACP, a renowned medical professional affiliated with the University of Pittsburgh Medical Center (UPMC), recently conducted a comprehensive analysis of the phase 3 KEYNOTE-716 study, focusing on the comparison between pembrolizumab and placebo as adjuvant therapy in stage IIB or IIC melanoma patients. The study’s final analysis examined distant metastasis-free survival, a crucial endpoint in evaluating the efficacy of adjuvant therapies. Melanoma, a type of skin cancer, can progress to advanced stages, leading to distant metastasis and reduced survival rates. Adjuvant therapies aim to prevent or delay cancer recurrence after surgical removal of the primary tumor, potentially…
Swetha Kambhampati, MD from the City of Hope talks about the ASCO 2023 abstract about Mantle Cell Lymphoma Real-World Outcomes of Brexu-cel A CIBMTR Subgroup Analysis by Prior Treatment.
The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced colorectal cancer. As part of the study, an analysis was conducted to assess the adverse events of special interest associated with fruquintinib treatment. Cathy Eng, MD, FACP, FASCO, from Vanderbilt Health, played a pivotal role in this analysis. The findings of the study provide valuable insights into the safety profile of fruquintinib and its potential as a treatment option for patients with advanced colorectal cancer. The FRESCO-2 study enrolled a large cohort of patients with advanced colorectal cancer who had…
Ferdinandos Skoulidis, MD, PhD, from the MD Anderson Cancer Center, presented the results of biomarker subgroup analyses from the phase 3 CodeBreaK 200 trial. The study evaluated the efficacy of sotorasib compared to docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation, a common genetic alteration in lung cancer. The CodeBreaK 200 trial enrolled patients with previously treated KRAS G12C-mutated NSCLC, which represents a subset of patients with limited treatment options. The study aimed to assess the efficacy and safety of sotorasib, a targeted therapy designed to inhibit the abnormal signaling caused by the…
J. Randolph Hecht, MD from UCLA Health is conducting a phase 3 clinical trial called STELLAR-303 to evaluate the efficacy and safety of a novel multi-kinase inhibitor (MKI) called XL092 in combination with atezolizumab, an immune checkpoint inhibitor (ICI), compared to regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). The trial aims to address the limited treatment options available for patients who have progressed after front-line chemotherapy. The prognosis for patients with mCRC is generally poor, with a 5-year survival rate of only 14%. While regorafenib and trifluridine-tipiracil are approved for third-line or later treatment, the survival benefit…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib) as a first-line treatment for advanced renal cell carcinoma (RCC). The primary analysis of the study demonstrated a significant improvement in progression-free survival and a meaningful improvement in overall survival, response rate, and complete response rate compared to the standard treatment, Sunitinib. These positive results led to the approval of the KEYTRUDA plus LENVIMA combination as an established standard of care option for first-line RCC. With an additional two years of follow-up, the final pre-specified…
This is a deep dive into the groundbreaking NAPOLI-3 Trial, a study that has generated significant interest and discussion in the medical community. Particularly among oncologists specializing in pancreatic cancer. In this article, we will delve into the complexities and outcomes of this notable study, shedding light on its potential implications for the future of pancreatic cancer treatment. The NAPOLI-3 Trial’s focus is on advanced pancreatic cancer, a disease notorious for its aggressive nature and limited treatment options. The study compared the efficacy and safety of three different treatment regimens (each with their own distinct benefits and drawbacks): NALIRIFOX FOLFIRINOX…
Adam Brufsky, MD, PhD from the University of Pittsburgh discussed the higher risk of recurrence in certain breast cancer patients and the need for additional therapies beyond hormonal therapy and chemotherapy. He highlighted that hormone receptor-positive (HR-positive), HER2-negative breast cancer represents about 60-70% of all breast cancer cases, and approximately 20% of all breast cancer patients would be considered for additional therapies. The NATALEE trial evaluated the addition of Ribociclib, a CDK4/6 inhibitor, to hormonal therapy for adjuvant treatment in patients with HR-positive, HER2-negative early-stage breast cancer. The study included patients with stage 2 and stage 3 breast cancer who…
Omid Hamid, MD from The Angeles Clinic & Research Institute reports on the best Cutaneous Treatments from ASCO 2023 and the future of this disease state.
Dr. Monica Niger, from Fondazione IRCCS Istituto Nazionale Tumori, provided a summary of the NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel study. Pancreatic cancer is known for its aggressive nature and limited effective treatment options. The standard first-line chemo therapies have been FOLFIRINOX and nab-paclitaxel. The NAPOLI-3 trial, the first positive Phase 3 trial since 2013, demonstrated that NALIRIFOX, a triple regimen, outperformed gemcitabine plus nab-paclitaxel in improving overall survival (OS) and progression-free survival (PFS) for pancreatic cancer patients. However, since NALIRIFOX is similar to FOLFIRINOX in terms of regimen and potential effects, the researchers wanted to understand the comparative…
Dr. Katherine Peters from Duke University Medical Center discussed the current treatments and their limitations for low-grade glioma patients with isocitrate dehydrogenase (IDH) mutations. These treatments include surgery, chemotherapy, and radiation therapy, but they can cause neurologic injury, bone marrow suppression, toxicities, fertility issues, and cognitive dysfunction, leading to a decline in quality of life. IDH1 and IDH2 mutations were discovered in 2009 and were found to confer a prognostic advantage and drive the development of gliomas. The latest World Health Organization (WHO) guidelines in 2021 incorporated these mutations into the integrated diagnosis for patients, considering their impact on outcomes…
High-grade gliomas represent a significant burden in neuro-oncology, affecting thousands of individuals worldwide each year. Gliomas, a form of brain cancer, have been the subject of intense research, with scientists and clinicians striving to improve survival rates and patient outcomes. Now, there is a game-changer in the field: Ruxolitinib. With the advent of innovative therapeutic strategies such as Janus kinase (JAK) inhibitors, like Ruxolitinib, there is a glimmer of hope on the horizon. As David M. Peereboom, MD, explained in his recent interview at ASCO 2023, “the JAK/STAT pathway, when it’s dysregulated, stimulates the growth of lots of different types…
“Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the MonumenTAL-1 study, focusing on the bispecific antibody talquetamab as a potential treatment option for relapsed/refractory multiple myeloma. Talquetamab has two domains—a GPRC5D-targeting domain for myeloma cells and a CD3 receptor for T-cells, connecting the two and enabling T-cell recognition and attack against myeloma cells. The inclusion criteria for the study required patients with pre-treated relapsed multiple myeloma who had at least three prior lines of treatment, including exposure to an IMIT protosome inhibitor and CD38 antibody. The study consisted of…
Introduction to Locally Advanced Breast Cancer Breast cancer is one of the most common types of cancer diagnosed in women worldwide. It’s a condition that comes in many forms and stages, each with its own set of characteristics, treatment options, and prognoses. One such stage that requires our attention and understanding is locally advanced breast cancer. The term LABC or locally advanced breast cancer is a term used to describe cancer that is larger in size, generally greater than 5 cm, and may have spread to nearby tissues such as the skin or chest wall, or to lymph nodes within…
Dr. Timothy Cloughesy, a prominent physician from UCLA Health, conducted the INDIGO clinical trial to evaluate the efficacy of Vorasidenib, an IDH inhibitor, in patients with IDH mutant low-grade glioma. The primary endpoint of the trial was progression-free survival (PFS). The results of the trial demonstrated a significant difference in PFS between the placebo and treatment groups. In the placebo group, tumors started to grow significantly within 11 months, while the treatment group experienced a median PFS of 27 months. This stark contrast indicated the effectiveness of Vorasidenib, supported by the P-values and hazard ratios. The trial also underwent…
Dr. Brian Hill, MD, PhD, from the Cleveland Clinic presented a study conducted through the Alliance and US cooperative groups, including ECOG and SWOG, called the A041702 study. This randomized phase 3 trial focused on previously untreated CLL patients over the age of 70. The study aimed to determine whether the addition of Venetoclax to Ibrutinib and Obinutuzumab would improve progression-free survival through a response-adapted use of Venetoclax for one year of therapy. The study compared two treatment arms. In the standard arm, patients received Ibrutinib and Obinutuzumab for one year, with Ibrutinib continued afterward. In the experimental arm,…
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and compared it to the outcomes observed in the CARTITUDE-1 clinical trial. They found that a significant percentage of patients (57%) in the study population would have been ineligible for participation in the trial. The most common reasons for ineligibility were cytopenias, oligo or non-story disease, organ dysfunctions, poor ECOG performance status, prior BCMA exposure, and the presence of plasma cell leukemia. The overall response rate (ORR) in the study population treated with SOC cilta-cel was 89%, with a complete…
Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety of ruxolitinib, an inhibitor of the JAK/STAT pathway, in treating high-grade glioma patients. The JAK/STAT pathway, when dysregulated, promotes the growth of various cancer cells, including gliomas. The trial enrolled 60 patients, predominantly male, with a median age of 60 years. Patients were stratified based on their MGMT promoter methylation status, a biomarker associated with treatment response. Patients with methylated MGMT promoters received radiation, temozolomide, and ruxolitinib, while those with unmethylated MGMT received radiation and ruxolitinib alone. The…
In this article, we dive deep into one of the potential advancement in the the evolving realm of medical science – the introduction of a drug called Triapine. Researchers have been relentlessly seeking solutions that can offer better treatment modalities and improved patient outcomes. This pursuit is particularly significant in the case of locally advanced cervical and vaginal cancers, where survival rates are still lower than desired. Currently, the standard treatment for these cancers is cisplatin-based chemoradiation (CRT). However, recent advances have sought to incorporate additional therapies to improve treatment outcomes. This drug was investigated in a clinical trial named…
Head and neck cancer, collectively termed Head and Neck Cancer (HNC), is a group of biologically similar cancers that start in the mouth, nose, throat, larynx, sinuses, or salivary glands. Now, there is a new chance to defeat HNC: Enfortumab Vedotin. Globally, HNC is a significant health concern, accounting for an estimated 932,000 new cases and causing 467,000 deaths in 2020. A stark reality is the poor prognosis for patients with recurrent or metastatic HNC, where the median survival rate is less than one year. Currently, the first line of treatment for HNC often includes platinum-based chemotherapy and immunotherapy with…
Dr. Jessica Geiger from Cleveland Clinic presented an abstract at ASCO 2023 highlighting the potential of Enfortumab vedotin as a novel therapeutic option for head and neck cancer (HNC) patients with recurrent metastatic disease who have failed standard frontline treatments. This patient population faces a significant unmet need, as current treatments have limited efficacy. Enfortumab vedotin, an antibody drug conjugate, targets the Nectin-4 protein expressed in a majority of HNC patients and delivers intracellular chemotherapy to destroy cancer cells. The EV-202 study, a phase 2, single-arm, multi-cohort trial, enrolled heavily pretreated HNC patients who had exhausted standard treatment options…
Dr. Atulya Khosla discussed the “Saved by the Scan” public service advertising program initiated by the American Lung Association (ALA) and Baptist Health South Florida (BHSF). The program aimed to address low lung cancer screening rates among high-risk populations, particularly racial and ethnic minorities, with a focus on Hispanics in South Florida. To tackle this issue, the program utilized a multipronged approach, employing both traditional and digital communication modalities. Traditional methods included posters, billboards, and news channels, while newer channels such as social media and emails were also utilized. Approximately 130,000 emails were sent, with a 27% open rate…
Dr. Suneel Kamath from the Cleveland Clinic – Young onset colorectal cancer (yoCRC) has been increasing over the past few decades, and the reasons behind this rise are still not well understood. Dr. Suneel Kamath and his team conducted a study using metabolomics to gain insights into the underlying factors contributing to yoCRC. Metabolomics is a field that examines the breakdown products of the body’s metabolism, including genetic and environmental influences. The study involved patients from two biobanks at Cleveland Clinic. One biobank consisted of patients with early-stage colorectal cancer, while the other included patients with colorectal liver metastases.…
by Hope Rugo, MD – UCSF Dr. Hope S. Rugo is a highly respected oncologist and professor of medicine specializing in breast oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she serves as the Director of Breast Oncology and Clinical Trials Education. The phase 3 CAPItello-291 trial evaluated the combination of Capivasertib (C) and Fulvestrant (F) in patients with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC), focusing on the characterization and management of common adverse events (AEs). The trial demonstrated that adding C, a potent pan-AKT inhibitor, to F resulted in…
Locally advanced cervical cancer is a significant disease affecting young women, and the standard treatment options have not seen substantial improvements since 1999. The addition of cisplatin chemotherapy to radiation therapy became the standard of care, resulting in a 5-year survival rate of approximately 60% for patients with locally advanced disease. However, there is still a need for further advancements to enhance patient outcomes. Dr. Sudah Amarnath discusses, the NRG-GY006 clinical trial aimed to improve the outcomes for patients with locally advanced cervical or vaginal cancer by incorporating the ribonucleotide reductase inhibitor, triapine, into the cisplatin-based chemoradiation (CRT) regimen.…
Advanced Angiosarcoma (AS) is a rare and aggressive form of cancer that forms in the lining of blood vessels and lymph vessels. Characterized by rapid growth and high potential for metastasis, this disease presents unique challenges to medical professionals and patients alike. As per the American Cancer Society, angiosarcoma accounts for only a small fraction of all sarcomas, yet its impact is significant. The journey of treating advanced angiosarcoma remains full of obstacles. One of this obstacles is the limited amount of treatment options, especially after taxane chemotherapy. Taxanes, a class of drugs commonly used in the treatment of many…
In this enlightening interview, esteemed Oncologist Gary Schwartz, MD discusses the promising development and potential of Cabozantinib plus Nivolumab as a therapeutic approach in advanced Angiosarcoma. Drawing from his extensive experience and recent clinical trials, Dr. Schwartz delves into the efficacy and safety profile of this potent combination. He shares insights on how this regimen has shown substantial improvements in response rates and progression-free survival, and its potential role in reshaping the treatment landscape for patients with advanced Angiosarcoma. The interview concludes with a discussion on future directions, emphasizing the importance of continued research to unlock the full potential of…
ASCO 2023 Press Briefing June 6, 2024 with Julie Gralow, MD ASCO Chief Medical Officer
Join us in an insightful interview with renowned oncologist Dr. Emrullah Yilmaz, MD, PhD, as he discusses the potential of BCA101, a promising therapeutic candidate for Squamous Cell Cancer treatment. Dr. Yilmaz, with his wealth of knowledge and experience in the field, breaks down the science behind BCA101, its ongoing clinical trials, and its future implications in the fight against cancer. If you’re seeking a deep understanding of the latest advancements in cancer treatment, this conversation is not to be missed. Dive into this intriguing discussion and discover the potential of BCA101 in revolutionizing oncology.
Squamous Cell Cancer, also known as squamous cell carcinoma (SCC), is an uncontrolled growth of abnormal cells arising in the squamous cells, which make up the majority of the skin’s upper layers (epidermis). This form of skin cancer is known to affect millions of people globally each year. Being the second most common type of skin cancer, it is a health condition that can’t be ignored. The visual appearance of squamous cell cancer varies, but it most often occurs as a rough, scaly, and flat patch that can bleed if bumped or injured. At times, it can also present as…
The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in newly diagnosed high-grade glioma patients, discussed by Dr. Manmeet Ahluwalia, were presented at ASCO 2023. High-grade gliomas, particularly those with unmethylated MGMT, have poor outcomes despite advancements in surgery, radiation, and chemotherapy. The effectiveness of Temozolomide, an oral chemotherapy, is limited in these patients, providing only a 21-day advantage in glioblastoma cases. Moreover, combining new therapies with Temozolomide often leads to increased toxicity. The CRUX trial took a two-pronged approach. In the first arm, Ruxolitinib was combined with radiation…